Following the removal of the Caveat Emptor designation, Protext Mobility Inc. (OTC: TXTM) has entered a new phase of growth — one built on transparency, accountability, and leadership alignment.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will ...

The press release will be available in the Investors section of Cellectis’ website: Cellectis will not host a conference call to discuss these results. Our investors relations team remains available ...

About CorMedix CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases.

NEW YORK and VIENNA, Oct. 31, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, “HOOKIPA”) today announced the completion of the sale of its assets related to HOOKIPA’s HB-400 program and ...

MEAI is a novel, non-hallucinogenic neuroplastogen designed to modulate serotonin and dopamine pathways, potentially reducing cravings and supporting long-term recovery. This approach could offer a ...

Nathan Yee, Managing Partner of White Lion, commented, “We believe this is more than just an investment, it’s a blueprint for the next era of capital formation. By exchanging shares for Solana tokens, ...

The aim of the collaboration is to increase needle-free access within Egypt and regionally while broadening Egypt’s manufacturing capabilities. PharmaJet’s Tropis ® intradermal needle-free delivery ...

COPENHAGEN, Denmark, October 31, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business ...

Oral presentation name: Enobosarm in Combination With GLP-1RA is Selective for Fat Loss While Preserving Lean and Function Presenter: Mitchell Steiner, M.D., Chairman, President, and Chief Executive ...

In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnings Call. A live webcast of this ...

Following achievement of the Return Cap, a royalty-only tail period will commence, which entitles HCRx to a predefined, reduced share of royalties not to exceed $14.9 million per year; the tail period ...